血清生长分化因子-15与先天性心脏病患儿心功能的关系及其对心力衰竭的诊断价值

doi:10.7499/j.issn.1008-8830.2013.02.005

摘要
图/表
参考文献(12)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (992 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：探讨生长分化因子-15（GDF-15）与先天性心脏病患儿心功能的关系及其对心力衰竭的诊断价值。方法：2011年3月至2012年5月成都市妇女儿童中心医院就诊的先天性心脏病患儿97例，依据改良Ross评分法分为心力衰竭组（71例）和无心力衰竭组（26例）。ELISA法检测两组血清GDF-15和B型脑钠肽前体(NT-proBNP)水平，超声心动图检测左室射血分数(LVEF)。采用Spearman相关分析对GDF-15与改良Ross评分、LVEF及NT-proBNP的相关关系进行分析。绘制ROC曲线并计算GDF-15曲线下面积及诊断心力衰竭的截断值。结果：心力衰竭组患儿血清GDF-15和NT-proBNP水平较无心力衰竭组显著增高，LVEF明显降低，差异有统计学意义(P<0.01)。血清GDF-15水平与改良Ross评分及血清NT-proBNP水平呈正相关（分别r=0.705和0.810，P<0.01），与LVEF呈负相关（r=－0.421，P<0.01）。GDF-15诊断心力衰竭的ROC 曲线下面积为0.757，当GDF-15的诊断界值为1306 ng/L，敏感性和特异性分别为68.8%和71.2%。结论：先天性心脏病合并心力衰竭患儿血清GDF-15明显升高，血清GDF-15水平与先天性心脏病患儿心功能、LVEF及NT-proBNP水平均有不同程度的相关关系；GDF-15可能成为诊断小儿先天性心脏病合并心力衰竭的一项检测指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李焰
	王献民
	柳颐龄
	石坤
	杨艳峰
	郭永宏

关键词 ：生长分化因子-15, 先天性心脏病, 心力衰竭, B型脑钠肽前体, 左室射血分数, 儿童

Abstract：OBJECTIVE: To study the correlation between growth differentiation factor-15(GDF-15) and cardiac function in pediatric patients with congenital heart disease, and the diagnositic value of GDF-15 in heart failure(HF). METHODS: From March 2011 to May 2012, 97 pediatric patients with congenital heart disease(CHD) who consecutively attended Chengdu Women′s & Children′s Central Hospital were enrolled in the study and assigned to HF (patients with heart failure, n=71) and Non-HF(patients without heart failure, n=26) groups. HF was defined as patients presenting with modified Ross score≥3. Plasma concentrations of GDF-15 and NT-proBNP were determined using ELISA. Left ventricular ejection fraction(LVEF) was tested by echocardiography. The correlation between GDF-15 and modified Ross score, LVEF and NT-proBNP was evaluated with Spearman′s analysis. The area under the receiver-operating characteristic(ROC) curve for GDF-15 was examined, and the cut-off concentration of GDF-15 for diagnosing HF was detected. RESULTS: The HF group demonstrated higher levels of GDF-15 and NT-proBNP, and a lower LVEF level (P<0.01) than the Non-HF group. Plasma GDF-15 level was positively correlated with modified Ross score and plasma NT-proBNP comcentration (r=0.705, r=0.810 respectively; P<0.01), and negatively correlated with LVEF(r=-0.391, P<0.01). According to ROC analysis, the AUC of GDF-15 for detection of HF was 0.757. Sensitivity and specificity was 68.8% and 71.2% respectively for the cut-off value of 1306 ng/mL. CONCLUSIONS: Plasma GDF-15 levels are significantly elevated in children with HF induced by CHD. Plasma GDF-15 levels are related to cardiac function, LVEF and plasma concentration of NT-proBNP. GDF-15 may potentially indicate HF in pediatric patients with CHD.

Key words： Growth differentiation factor-15 Congenital heart disease Heart failure NT-proBNP Left ventricular ejection fraction Child

引用本文:

李焰,王献民,柳颐龄等. 血清生长分化因子-15与先天性心脏病患儿心功能的关系及其对心力衰竭的诊断价值[J]. 中国当代儿科杂志, 2013, 15(2): 95-98.

LI Yan,WANG Xian-Min,LIU Yi-Ling et al. Plasma concentration of growth-differentiation factor-15 in children with congenital heart disease: relation ship to heart function and diagnostic value in heart failure[J]. CJCP, 2013, 15(2): 95-98.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2013.02.005 或 http://www.zgddek.com/CN/Y2013/V15/I2/95

	［1］DominguezRodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction［J］. Am J Cardiol, 2011, 108(7): 955-958.
	［2］Dinh W, Futh R, Lankisch M, Hess G, Zdunek D, Scheffold T, et al. Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction?［J］. Arq Bras Cardiol, 2011, 97(1): 65-75.
	［3］Wang F, Guo Y, Yu H, Zheng L, Mi L, Gao W. Growth differentiation factor 15 in different stages of heart failure: potential screening implications［J］. Biomarkers, 2010, 15(8): 671-676.
	［4］Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial［J］. Circulation, 2010, 122(14): 1387-1395.
	［5］中华医学会儿科学分会心血管学组, 《中华儿科杂志》编辑委员会. 小儿心力衰竭诊断与治疗建议［J］. 中华儿科杂志, 2006, 44(10): 753-757.
	［6］Laer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters［J］. Am Heart J, 2002, 143(5): 916-922.
	［7］Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure［J］. J Am Coll Cardiol, 2007, 50(11): 1054-1060.
	［8］Norozi K, Buchhorn R, Yasin A, Geyer S, Binder L, Seabrook JA, et al. Growth differentiation factor 15: an additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects?［J］. Am Heart J, 2011, 162(1): 131-135.
	［9］Ross RD. Grading the graders of congestive heart failure in children［J］. J Pediatr, 2001, 138(5): 618-620.
	［10］张鹤, 李玖军. 先天性心脏病患儿血浆脑钠肽水平与左心功能的关系［J］. 中国当代儿科杂志, 2012, 14(1): 42-44.
	［11］Kempf T, Wollert KC. Growth differentiation factor-15: a new biomarker in cardiovascular disease［J］. Herz, 2009, 34(8): 594-599.
	［12］Raedle-Hurst TM, Koenigstein K, Gruenhage F, Raedle J, Herrmann E, Abdul-Khaliq H. Growth differentiation factor 15—an early marker of abnormal function of the Fontan circuit in patients with univentricular hearts［J］. Am Heart J, 2010, 160(6): 1105-1112.